Editorial introductions Flexner, Charles W.; Francois Venter, Willem Daniel; Clayden, Polly Flexner, Charles W.; Francois Venter, Willem Daniel; Clayden, Polly Less Current Opinion in HIV and AIDS. 12(4):v-vi, July 2017. Favorite PDF Permissions Buy
Why a universal antiretroviral regimen? Flexner, Charles W.; Clayden, Polly; Venter, Willem D.F. Flexner, Charles W.; Clayden, Polly; Venter, Willem D.F. Less Current Opinion in HIV and AIDS. 12(4):315-317, July 2017. Favorite PDF Permissions Buy
Candidates for inclusion in a universal antiretroviral regimen: dolutegravir Cahn, Pedro Cahn, Pedro Less Current Opinion in HIV and AIDS. 12(4):318-323, July 2017. Abstract Abstract Favorite PDF Permissions Buy
Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide Gotham, Dzintars; Hill, Andrew; Pozniak, Anton L. Gotham, Dzintars; Hill, Andrew; Pozniak, Anton L. Less Current Opinion in HIV and AIDS. 12(4):324-333, July 2017. Abstract Abstract Favorite PDF Permissions Buy
Candidates for inclusion in a universal antiretroviral regimen: are lamivudine and emtricitabine interchangeable? Ford, Nathan; Vitoria, Marco; Doherty, Meg; More Ford, Nathan; Vitoria, Marco; Doherty, Meg; Gray, Andy Less Current Opinion in HIV and AIDS. 12(4):334-338, July 2017. Abstract Abstract Favorite PDF Permissions Buy
Antiretroviral dose optimization: the future of efavirenz 400 mg dosing Boffito, Marta; Lamorde, Mohammed; Watkins, Melynda; More Boffito, Marta; Lamorde, Mohammed; Watkins, Melynda; Pozniak, Anton Less Current Opinion in HIV and AIDS. 12(4):339-342, July 2017. Abstract Abstract Favorite PDF Permissions Buy
Universal antiretroviral regimens: thinking beyond one-pill-once-a-day Jacobson, Jeffrey M.; Flexner, Charles W. Jacobson, Jeffrey M.; Flexner, Charles W. Less Current Opinion in HIV and AIDS. 12(4):343-350, July 2017. Abstract Abstract Favorite PDF Permissions Buy
The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen Venter, Willem D.F.; Clayden, Polly; Serenata, Celicia; More Venter, Willem D.F.; Clayden, Polly; Serenata, Celicia; for the OPTIMIZE Consortium Less Current Opinion in HIV and AIDS. 12(4):351-354, July 2017. Abstract Abstract Favorite PDF Permissions Go to Full Text of this Article Open
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings Maartens, Gary; Boffito, Marta; Flexner, Charles W. Maartens, Gary; Boffito, Marta; Flexner, Charles W. Less Current Opinion in HIV and AIDS. 12(4):355-358, July 2017. Abstract Abstract Favorite PDF Permissions Buy
Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding Slogrove, Amy L.; Clayden, Polly; Abrams, Elaine J. Slogrove, Amy L.; Clayden, Polly; Abrams, Elaine J. Less Current Opinion in HIV and AIDS. 12(4):359-368, July 2017. Abstract Abstract Favorite PDF Permissions Buy
Prioritizing the most needed formulations to accelerate paediatric antiretroviral therapy scale-up Penazzato, Martina; Palladino, Claudia; Sugandhi, Nandita; More Penazzato, Martina; Palladino, Claudia; Sugandhi, Nandita; on behalf of the Paediatric ARV Drug Optimization 3 Meeting participants Less Current Opinion in HIV and AIDS. 12(4):369-376, July 2017. Abstract Abstract Favorite PDF Permissions Buy
Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countries Seden, Kay; Boffito, Marta; Khoo, Saye Seden, Kay; Boffito, Marta; Khoo, Saye Less Current Opinion in HIV and AIDS. 12(4):377-382, July 2017. Abstract Abstract Favorite PDF Permissions Buy
Accelerating access and scale-up of optimized ART in low-income and middle-income countries: a call for a coordinated end-to-end approach Harris, Emily; Pérez-Casas, Carmen; Barnhart, Matthew; More Harris, Emily; Pérez-Casas, Carmen; Barnhart, Matthew; Lin, Amy H.; Ferris, Danielle; Ajose, Olawale; Burgess, Emma K.; Fowler, Rachel Less Current Opinion in HIV and AIDS. 12(4):383-389, July 2017. Abstract Abstract Favorite PDF Permissions Buy
Can the generic antiretroviral industry support access to a universal antiretroviral regimen? Amole, Carolyn D.; Middlecote, Caroline; Prabhu, Vineet R.; More Amole, Carolyn D.; Middlecote, Caroline; Prabhu, Vineet R.; Kumarasamy, N. Less Current Opinion in HIV and AIDS. 12(4):390-397, July 2017. Abstract Abstract Favorite PDF Permissions Buy
The role of activists in access to HIV and tuberculosis treatment and prevention Geffen, Nathan Geffen, Nathan Less Current Opinion in HIV and AIDS. 12(4):398-402, July 2017. Abstract Abstract Favorite PDF Permissions Buy
A cost-savings analysis of a candidate universal antiretroviral regimen Ripin, David; Prabhu, Vineet R. Ripin, David; Prabhu, Vineet R. Less Current Opinion in HIV and AIDS. 12(4):403-407, July 2017. Abstract Abstract Favorite PDF Permissions Buy
Dealing with large-scale supply lines when introducing new regimens Malati, Christine; Rosenfeld, Joshua; Mowafy, Sherif; More Malati, Christine; Rosenfeld, Joshua; Mowafy, Sherif; Rittmiller, Trevor; Kuritsky, Joel; Crowley, John Less Current Opinion in HIV and AIDS. 12(4):408-413, July 2017. Abstract Abstract Favorite PDF Permissions Buy
When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank Vitoria, Marco; Ford, Nathan; Clayden, Polly; More Vitoria, Marco; Ford, Nathan; Clayden, Polly; Pozniak, Anton L.; Hill, Andrew M. Less Current Opinion in HIV and AIDS. 12(4):414-422, July 2017. Abstract Abstract Favorite PDF Permissions Go to Full Text of this Article Open
